Popular Stories
Avise Analytics | TOP 5 PROMISING STEM CELL STOCKS
Covering U.S listed biotech companies that are either developing or has developed most advanced stem cell therapies.
Stem Cell Technology, Regenerative Medicine Market, VistaGen Therapeutics, VTGN, Bio-Pharmaceutical, Cytori Therapeutics, CYTX, Speciality Therapeutics, BioRestorative Therapies, OTCQB, BRTX, Chronic Back Pain, Cesca Therapeutics, NASDAQ, KOOL, Cryo-Cell International, OTCPK, CCEL
17452
post-template-default,single,single-post,postid-17452,single-format-standard,ajax_fade,page_not_loaded,,side_area_uncovered_from_content,qode-child-theme-ver-1.0.0,qode-theme-ver-7.4,wpb-js-composer js-comp-ver-5.0.1,vc_responsive

TOP 5 PROMISING STEM CELL STOCKS

19 Jan TOP 5 PROMISING STEM CELL STOCKS

Stem Cell Technology is a major component of the global regenerative medicine market. The increase in geriatric population and augmented spending on research and development for offering viable alternatives to traditional healthcare options is propelling the growth in the market.

Despite facing stringent regulatory limitations and ethical concerns, the stem cell regeneration is witnessing a welcoming change in terms of increased awareness, formulation of regulations and regulatory acceptance. According to the latest research conducted by Infinity Research Limited, the global stem cell industry is poised to grow at a CAGR of whooping 36.52% by 2021, attracting a lot of interest.

Interestingly, U.S is one of the leading investors in the research and development of stem cell regenerative therapies with North America poised to amass a leading market share of 39.7% globally by 2024. According to research and markets, the industry is expected to reach USD 5056.4 million by end of 2024, to achieve Y-o-Y growth rate of 5.6%

Here is a look at the top 5 promising U.S listed stem cell stocks .

VistaGen Therapeutics (NASDAQ: VTGN)

Market cap: 49.381M; current share price 1.59 USD

VTGN data by YCharts

VistaGen Therapeutics, a clinical – stage bio-pharmaceutical company engaged in creating medicines for central nervous system has received a patent related to certain methods of production for AV-101.

Pipeline

Source: Company

Shawn Singh, Chief Executive Officer of VistaGen, commented, “Receiving this patent in Hong Kong, along with its counterpart patent in China, strengthens our commercial protection in two key markets in Asia and is another significant step forward in our global IP plan for AV-101.”

Cytori Therapeutics (NASDAQ: CYTX)

Market Cap: 3.997M; current share price: 0.27 USD

CYTX data by YCharts

Cytori is engaged in the development of speciality therapeutics using a combination of its proprietary cell therapy and nano particle platforms to treat a variety of oncologic and degenerative conditions.

Pipeline

Source: Company Presentation

It recently received an approval for its Elution Cell Therapy System consumable bundle in Japan, allowing it to expand its commercial efforts in Japan. It has also outsourced a crucial part of the production process of its Celution Cell Therapy consumables.

BioRestorative Therapies (OTCQB: BRTX)

Market cap: 7.527M; current share price 0.80 USD

BRTX data by YCharts

BioRestorative is actively involved in the developing a treatment for chronic back pain caused by disc degeneration and metabolic disorders. It holds an open IND (Investigational New Drug) which is scheduled for a phase II trial protocol in 2019.

Pipeline

Source: Company

Its proprietary ThermoSterm program that uses brown adipose-derived (“brown fat”) stem cells to generate new brown fat tissue has received a notice of allowance for a key metabolic patent in the U.S, having therapeutic uses in the treatment of degenerative and metabolic disorders

Cesca Therapeutics (NASDAQ: KOOL)

Market Cap: 6.062M; current share price: 0.29 USD

KOOL data by YCharts

Cesca is engaged in the delivery of automated technologies for cell-based therapeutics, also manufacturing automated clinical biobanking, and automation of immune-oncology. It recently received a 510(K) Clearance from U.S Food and Drug Administration (FDA) for its clinical blood banking application AXP II AutoExpress Platform II.

Philip Coelho, ThermoGenesis’ Chief Technology Officer said in a press release that, “Receipt of 510(K) clearance from the FDA for the AXP II is an important step for the Company and may expand market adoption as it provides cord blood bank customers with an automated system that achieves mononuclear cell (MNC) recoveries >90% and CD34+ stem and progenitor cell recoveries > 95%. The company intends to build on this momentum as we continue to support clinical development in the significant market of cell-based therapeutics, particularly in the immuno-oncology field, where we already have begun to play an important role.”

Cryo-Cell International (OTCQB: CCEL)

Market cap: 58.818M; current share price 7.54 USD

CCEL data by YCharts

The company is into stem cell cryopreservation service and to advance regenerative medicine. The Prepacyte CB segment refers to the processing technology used to process umbilical cord blood stem cells. It functions on the principles of cellular processing, Cryogenic Storage and Prepacyte CB segments.

Source: Company

It harvests and preserves umbilical cord blood and tissue cells for future use. It also enjoys the distinction of being awarded with FACT (the Foundation for the Accreditation for Cellular Therapy) accreditation. The company declared it third quarter results recently and reported consolidated revenues of $7.9 million compared to $6.9 million for the third quarter of fiscal 2017.

These are the stocks to watch out for in case you are looking to invest in the stem cell industry.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

No Comments

Post A Comment

WordPress Video Lightbox Plugin